CLINICAL LABS & IMMUNODIAGNOSTICS
Diabetes is relentless. At the current growth rate, diabetes threatens to overwhelm global health care systems in the future. The need for innovation and leadership in the prevention and management of diabetes has never been more important.
Our comprehensive diabetes menu offers outstanding quality and accuracy enabling your lab to do more with less and clinicians to make better treatment decisions to improve the patient care.
Our new VITROS® A1c Solution is revolutionizing how your lab can help clinicians treat patients.
Traceable to standardized materials and good correlation with other commercial assays
Optimizes reagent use and decreases waste
Decreases the number of calibration events
No cuvettes to wash, no probes to clean, no risk of sample nor reagent carry-over
Highly specific antibodies and chemistry detection methods
None-to-minimal cross-reactivity and minimal interferences
Break free from the complexities of whole blood A1c testing with our novel enzymatic VITROS® A1c Slides and enhanced VITROS® Enabling Technologies so that you can report A1c results confidently, while increasing productivity and efficiency.
Its multi-layer Dry Slide design delivers exceptional performance that is certified by the National Glycohemoglobin Standardization Program (NGSP) and is free from hemoglobin variant interference* to bring you result peace of mind.
*Up to HbS ≤ 41%, HbC ≤ 36%, HbD ≤ 41%, HbE ≤ 40%
1. D48434 Whole Blood MicroSlide Processing Theory Guide
2. Up to HbS ≤ 41%, HbC ≤ 36%, HbD ≤ 41%, HbE ≤ 40%, HbA2 ≤ 7%, HbF ≤ 15%
3. National Glycohemoglobin Standardization Program. Certified Methods. http://www.ngsp.org/certified.asp
The VITROS Insulin assay has excellent performance to help clinicians understand the cause of a patient’s hypoglycemia or differentiate between type I and type II diabetes. Measuring insulin levels can evaluate the production and resistance.
The VITROS Insulin assay antibody is highly specific for insulin detection, with no cross-reactivity to C-peptide or Proinsulin.* Importantly it has insignificant or no cross-reactivity to insulin analogs commonly used in diabetes treatment.
*Ding, Qian. Performance Comparison of VITROS Immunodiagnostic Products Insulin Assay. Ortho Clinical Diagnostics PR-03149. 2017
C-peptide testing provides a reliable assessment of beta-cell function and aids in differentiating Type I, Type II diabetes and MODY. Differentiating the diabetes type at clinical presentation is challenging and treatment decisions can improve with clear answers.
The VITROS C-Peptide assay uses an antibody highly specific for C-Peptide detection with no significant cross-reactivities to insulin, proinsulin, glucagon, calcitonin or somatostatin.
Diabetic Ketoacidosis (DKA) can manifest as the first sign of diabetes for patients with type 1 and can occur in severe cases of hyperglycemia for patients with type 2 diabetes.
The ß-Hydroxybutyrate LiquiColor® Assay* quantitatively measures ß-Hydroxybutyrate (BHB), the major ketone by product from the body metabolizing stored fat in the liver when glucose is not available. The buildup of ketones in the blood can be fatal if left unchecked.
The ß-Hydroxybutyrate LiquiColor® Assay* is highly specific and is not susceptible to interferences for excellent performance on VITROS Systems. This lifesaving test is ready when you are.
*MicroTip Partnership Assay. May not be available in all countries.
Imagine going from clutter to clarity and having seamless control of your lab. Our Ortho Care® Services and Informatics gives you the freedom to focus on patient care.
Is it time to change the way you see your lab? Simplify data to unburden you from the disruptions, complexities and distractions that pull your focus away from patient care. See how network insights, open connectivity and quality management can drive the change your lab needs.